Association of Potassium Level at Discharge with Long-Term Mortality in Hospitalized Patients with Heart Failure

Dyskalemia (hypokalemia and hyperkalemia) is a common comorbidity of heart failure (HF). Although dyskalemia is associated with poor prognosis, different prognostic impacts of hypo- and hyperkalemia remain vastly unclear. This study investigated the association of dyskalemia with prognosis in HF patients, especially the mode of death and left ventricular ejection fraction (LVEF). The multicenter study included 3398 patients hospitalized for HF. Patients were divided into three groups based on serum potassium levels at discharge: hypokalemia (<3.5 mEq/L; n = 115 (3.4%)), normokalemia (3.5–5.0 mEq/L; n = 2960 (87.1%)), and hyperkalemia (≥5.0 mEq/L; n = 323 (9.5%)). Two-year all-cause, cardiac, and non-cardiac mortality was evaluated. Association of serum potassium with two-year mortality demonstrated a U-shaped curve, with a worse prognosis for patients with hypokalemia. All-cause mortality at two-years did not differ among the three groups. Hypokalemia was associated with 2-year cardiac death (adjusted hazard ratio (HR), 2.60; 95% confidence interval (CI), 1.20–5.64) in HF with reduced ejection fraction (HFrEF; LVEF < 40%), but not in non-HFrEF. Regardless of LVEF, hyperkalemia was not independently associated with any mortality. Hypokalemia was independently associated with cardiac death, particularly in HFrEF patients. Such an association was not observed in hyperkalemia regardless of LVEF.

[1]  M. Kearney,et al.  Reduction of heart failure guideline‐directed medication during hospitalization: prevalence, risk factors, and outcomes , 2022, ESC heart failure.

[2]  H. Thiele,et al.  Guideline‐directed medical therapy in patients undergoing transcatheter edge‐to‐edge repair for secondary mitral regurgitation , 2022, European journal of heart failure.

[3]  G. Filippatos,et al.  Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter‐defibrillator for primary prevention? , 2022, European journal of heart failure.

[4]  C. Specchia,et al.  Prognostic significance of serum potassium in patients hospitalized for acute heart failure , 2022, ESC heart failure.

[5]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[6]  T. N. Harrison,et al.  Representativeness of the GALACTIC‐HF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction , 2022, Journal of the American Heart Association.

[7]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[8]  Y. Shiraishi,et al.  Different Impact of Beta-Blockers on Long-Term Mortality in Heart Failure Patients with and without Chronic Obstructive Pulmonary Disease , 2021, Journal of clinical medicine.

[9]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[10]  L. Lund,et al.  Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[11]  G. Filippatos,et al.  Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry , 2020, European journal of heart failure.

[12]  K. Fukuda,et al.  Prediction of sudden cardiac death in Japanese heart failure patients: international validation of the Seattle Proportional Risk Model. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[13]  L. Lund,et al.  Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry , 2020, European journal of heart failure.

[14]  W. Tay,et al.  Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN‐HF registry , 2019, European journal of heart failure.

[15]  Mohamed O. Saad,et al.  Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study , 2019, BMC Cardiovascular Disorders.

[16]  A. Donato,et al.  Influence of abnormal potassium levels on mortality among hospitalized heart failure patients in the US: data from National Inpatient Sample , 2019, Journal of community hospital internal medicine perspectives.

[17]  C. Linde,et al.  Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK , 2019, ESC heart failure.

[18]  Akshay S. Desai,et al.  Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas , 2018, European journal of heart failure.

[19]  Y. Izumiya,et al.  Serum Potassium and Cardiovascular Events in Heart Failure With Preserved Left Ventricular Ejection Fraction Patients , 2018, American journal of hypertension.

[20]  A. Gavazzi,et al.  Prevalence and prognostic impact of non‐cardiac co‐morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community‐based study , 2018, European journal of heart failure.

[21]  P. Ponikowski,et al.  Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF , 2018, European journal of heart failure.

[22]  M. Metra,et al.  Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality , 2017, Circulation.

[23]  M. Ochiai,et al.  The association between high‐dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure , 2017, ESC heart failure.

[24]  L. Køber,et al.  Associations of serum potassium levels with mortality in chronic heart failure patients , 2017, European heart journal.

[25]  Zhilin Qu,et al.  Electrophysiology of Hypokalemia and Hyperkalemia. , 2017, Circulation. Arrhythmia and electrophysiology.

[26]  P. Ponikowski,et al.  Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). , 2017, The American journal of cardiology.

[27]  H. Kasanuki,et al.  Etiology of Heart Failure and Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection Fraction. , 2016, The American journal of cardiology.

[28]  K. Fukuda,et al.  Validation of the Get With The Guideline-Heart Failure risk score in Japanese patients and the potential improvement of its discrimination ability by the inclusion of B-type natriuretic peptide level. , 2016, American heart journal.

[29]  J. Weiss,et al.  Molecular Basis of Hypokalemia-Induced Ventricular Fibrillation , 2015, Circulation.

[30]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.

[31]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Journal of the American College of Cardiology.

[32]  P. Ponikowski,et al.  Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.

[33]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[34]  Subhash Banerjee,et al.  Predictors of hyperkalemia and death in patients with cardiac and renal disease. , 2012, The American journal of cardiology.

[35]  B. Kaufmann,et al.  Clinical and pharmacological investigations of the new saluretic azosemid , 1978, European Journal of Clinical Pharmacology.

[36]  B. Palmer Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.

[37]  A. Struthers,et al.  What is the optimal serum potassium level in cardiovascular patients? , 2004, Journal of the American College of Cardiology.

[38]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[39]  R. Tannen Diuretic-induced hypokalemia. , 1985, Kidney international.